Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutical excipients, such as pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprising of hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate products. Hunan Er-Kang Pharmaceutical Co., Ltd was founded in 2003 and is based in Changsha, China.
Research context
Hunan Er-Kang Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Hunan Er-Kang Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 11.3% below its 200 day moving average.
From a valuation standpoint, the stock is 67.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Hunan Er-Kang Pharmaceutical Co., Ltd's total revenue sank by 3.2% to $579M since the same quarter in the previous year.
Its net income has increased by 216.3% to $115M since the same quarter in the previous year.
Finally, its free cash flow grew by 204.9% to $95M since the same quarter in the previous year.
Based on the above factors, Hunan Er-Kang Pharmaceutical Co., Ltd gets an overall score of 3/5.